Literature DB >> 23826472

A rare bacteremia caused by Cedecea davisae in patient with chronic renal disease.

Avi Peretz1, Claudia Simsolo, Evgeny Farber, Anna Roth, Diana Brodsky, Farid Nakhoul.   

Abstract

PATIENT: Female, 77. FINAL DIAGNOSIS: Bacteremia. SYMPTOMS: Chills • diarrheafevernausea. MEDICATION: - CLINICAL PROCEDURE: X-Ray • CBC • urine and blood cultur. SPECIALTY: Infectious diseases.
OBJECTIVE: Rare disease.
BACKGROUND: Cedecea davisae is a gram negative, oxidase negative bacilli that include 5 species. In the medical literature there are very few reports that describe infections caused by different species of the Cedecea genus. CASE REPORT: In this paper we report a fourth case of bacteremia in a 77 year-old patient with a chronic renal disease that was successfully treated with ceftazidim and ciprofloxacin. Additionally, we present a review of all the reported infections that were caused by C. davisae.
CONCLUSIONS: Five cases (not including our report) of Cedecea bacteremia were reported so far. Cedecea infections and particularly C. davisae infections can be difficult to treat due to the antibiotic resistance of the bacterium. Therefore we propose to consider treating C. davisae bacteremia with a combined antibiotic treatment until getting laboratory results for antibiotic-sensitivity tests.

Entities:  

Keywords:  Cedecea davisae; bacteremia

Year:  2013        PMID: 23826472      PMCID: PMC3700469          DOI: 10.12659/AJCR.889285

Source DB:  PubMed          Journal:  Am J Case Rep        ISSN: 1941-5923


Background

Cedecea are gram negative, oxidase negative bacilli that include 5 species. This genus was designated by the Centers for Disease Control (CDC) in 1981 as a separate genus in the Enterobacteriaceae family. The Cedecea bacteria are closely related to the Serratia bacteria but do not hydrolyze DNA or gelatin [1]. In the medical literature there are very few reports that describe infections such as pneumonia, soft tissues infections, urinary tract infections and sepsis, which were caused by different species of the Cedecea genus such as C. neteri and C. lapagei. In most cases, these infections appeared in immunocompromised patients [2-7]. In the present case report we describe a third case of sepsis which caused by Cedecea davisae in a patient with chronic renal disease stage V and to present a review of all literature documented cases which were caused by C. davisae.

Case Report

A 77 year-old female patient with chronic kidney disease stage V, a history of diabetic nephropathy and hypertension, on hemodialysis treatment since 2008, was admitted to our Nephrology Department for a routine hemodialysis treatment on May 2012. During the hemodialysis treatment, the patient started to complain of chills, fever, nausea and leg cramps. Later, non-hemorrhagic diarrhea and vomiting appeared lasting a few days. On physical examination, the patient was hemodynamically stable with a blood pressure of 200/90 mm Hg and fever of 39.5°C. Chest X-ray revealed no evidence of inflammatory infiltration, 6,800 leukocytes per mcL on cell blood count test, with 90% neutrophils. Urine culture, 2 sets of blood culture and culture from the Permacat catheter tip were drawn and antibiotic treatment was started with vancomycin and gentamicin. Urine culture was negative. However, all the blood cultures (Bactec FX system, BD, USA) and the catheter tip culture were positive, with gram negative bacilli growth on blood, chocolate and MacConkey agars. Later, these bacilli were defined as Cedecea davisae by an automatic microbial identification system, VITEK 2 (BioMérieux, Durham, NC) and by means of the molecular biology method of 16S RNA. In addition, an antibiogram test was performed in the Kirby-Bauer method (disk diffusion antibiotic sensitivity testing) in which we found that the bacterium was sensitive to amikacin, ceftazidim, ciprofloxacin, gentamicin, meropenem, trinethoprim/sulfa and levofloxacin, and resistant to ampicillin, ampicillin/sulbactam and cefazolin. Therefore the treatment was replaced with ciprofloxacin and ceftazidim. During the antibiotic therapy, no additional fever rises were seen and follow-up cultures that were drawn were sterile. The patient got released from the hospital after 4 hospitalization days in a stable state with a recommendation for further treatment with ciprofloxacin for 10 days (Table 1).
Table 1

All reported cases of Cedecea davisae infections.

Infection courseSource of isolateMedical historyAge/sexYear [reference]
Inpatient, febrile with pneumonia; defervesce within 11 days on cefazolinSputumDM, CHF, HTN65/F1981 [2]
Inpatient, with scrotal abscess; resolved in 5 days with tetracyclineScrotal abscessHTN, CHF, alcoholic hepatitis50/M1983 [3]
Inpatient who developed DIC, platelet count recovered on mezlocillin, gentamycin, clindamcinBloodHeart disease, bronchitis, COPD70/F1986 [4]
Inpatient, febrie, successfully treated with 12 days of cefotaxime, amikacinLeg ulcer, bloodDM67/M2008 [5]
Outpatient, afebrile, successfully treated with 21 days of ciprofloxacinOral ulcerS/P renal transplantation, DM, HTN42/M2009 [6]
Inpatient, febrile and pneumonia, successfully treated with ceftazidime, ciprofloxacin piperacillintazobactamBloodAML, C. diff colitis52/M2011 [7]
Inpatient, febrile wit Chills, vomiting and diarrhea; defervesce within 2 days on Ceftazidim and 12 days of ciprofloxacinBlood and permacat catheter tipDM, HTN, chronic renal disease77/M2012 [current case]

DM – diabetes mellitus; HTN – hypertension; CHF – congestive heart failure; COPD – chronic obstructive pulmonary disease; DIC – disseminated intravascular coagulation; AML – acute myeloid leukemia.

Discussion

In 1981, a gram negative, oxidase negative, fermentative bacillus formerly known as enteric group 15 of the family Entrobacteriacaeae, was designated as a new and a separate genus. This genus includes 5 different species [1]. In the medical literature there are a few documented cases in which these bacteria were isolated from various clinical specimens including sputum, urine, soft tissues and blood. Most of the isolates came from infections in immunocompromised patients. To the best of our knowledge, five cases (not including our report) of Cedecea bacteremia were reported so far. The first case was reported in 1982. Three out of these five Cedecea bacteremia cases were caused by C. davisae and the rest by C. lapagei and C. neteri[2,7]. Cedecea infections and particularly C. davisae infections can be difficult to treat due to the antibiotic resistance of the bacterium [5,8]. The previously described cases reported microbial resistance to cephalothin, cefuroxime, ceftazidim, ampicillin, tetracycline, cefoxitin, piperacillin, nitrofurntoin and ciprofloxacin. In our report we described another case of C. davisae bacteremia in a patient with chronic renal disease stage V that was successfully treated with ceftazidim and ciprofloxacin.

Conclusions

In this case report, we report for the first time on C. davisae isolation from Permacath catheter tip culture and on microbial resistance to ampicillin/sulbactam and cefazolin. Therefore we propose to consider treating C. davisae bacteremia with a combined antibiotic treatment until getting laboratory results for antibiotic-sensitivity tests.
  7 in total

1.  Cedecea lapagei bacteremia following cement-related chemical burn injury.

Authors:  M Dalamaga; K Karmaniolas; G Arsenis; M Pantelaki; K Daskalopoulou; E Papadavid; I Migdalis
Journal:  Burns       Date:  2008-05-07       Impact factor: 2.744

2.  Leg ulcer and bacteremia due to Cedecea davisae.

Authors:  Maria Dalamaga; Maria Pantelaki; Konstantinos Karmaniolas; Athina Matekovits; Konstantina Daskalopoulou
Journal:  Eur J Dermatol       Date:  2008 Mar-Apr       Impact factor: 3.328

Review 3.  Sirolimus oral ulcer with Cedecea davisae superinfection.

Authors:  H Mawardi; M Pavlakis; D Mandelbrot; S-B Woo
Journal:  Transpl Infect Dis       Date:  2010-10       Impact factor: 2.228

4.  Cedecea davisae bacteremia in a neutropenic patient with acute myeloid leukemia.

Authors:  Getahun Abate; Shahab Qureshi; Shirin A Mazumder
Journal:  J Infect       Date:  2011-04-27       Impact factor: 6.072

5.  Cedecea davisae isolated from scrotal abscess.

Authors:  B H Bae; S B Sureka
Journal:  J Urol       Date:  1983-07       Impact factor: 7.450

6.  Enteric group 15 (Enterobacteriaceae) associated with pneumonia.

Authors:  B H Bae; S B Sureka; J A Ajamy
Journal:  J Clin Microbiol       Date:  1981-11       Impact factor: 5.948

7.  Cedecea davisae bacteremia.

Authors:  S R Perkins; T A Beckett; C M Bump
Journal:  J Clin Microbiol       Date:  1986-10       Impact factor: 5.948

  7 in total
  7 in total

1.  TIR-only protein RBA1 recognizes a pathogen effector to regulate cell death in Arabidopsis.

Authors:  Marc T Nishimura; Ryan G Anderson; Karen A Cherkis; Terry F Law; Qingli L Liu; Mischa Machius; Zachary L Nimchuk; Li Yang; Eui-Hwan Chung; Farid El Kasmi; Michael Hyunh; Erin Osborne Nishimura; John E Sondek; Jeffery L Dangl
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-30       Impact factor: 11.205

2.  Characterization of a novel AmpC β-lactamase produced by a carbapenem-resistant Cedecea davisae clinical isolate.

Authors:  Nacim Ammenouche; Hervé Dupont; Hedi Mammeri
Journal:  Antimicrob Agents Chemother       Date:  2014-08-18       Impact factor: 5.191

3.  First Korean case of Cedecea lapagei pneumonia in a patient with chronic obstructive pulmonary disease.

Authors:  Sung Kuk Hong; Jee-Soo Lee; Eui-Chong Kim
Journal:  Ann Lab Med       Date:  2015-02-12       Impact factor: 3.464

4.  Urinary Catheter Colonization by Multidrug-Resistant Cedecea neteri in Patient with Benign Prostatic Hyperplasia.

Authors:  Peter S Ginn; Serina B Tart; Stephen M Sharkady; Dorothea K Thompson
Journal:  Case Rep Infect Dis       Date:  2018-07-11

5.  A Rare Case of Cedecea Davisae Bacteremia Presenting as Biliary Sepsis.

Authors:  Venkata Sowjanya Kanakadandi; Manbeer S Sarao; Jessica M Cunningham
Journal:  Cureus       Date:  2019-08-01

6.  AmpC hyperproduction in a Cedecea davisae implant-associated bone infection during treatment: a case report and therapeutic implications.

Authors:  Julia Notter; Salome N Seiffert; Maria Zimmermann-Kogadeeva; Anja Bösch; Robert Wenger; Carol Strahm; Manuel Frischknecht; David M Livermore; Baharak Babouee Flury
Journal:  BMC Infect Dis       Date:  2022-01-06       Impact factor: 3.090

7.  Silver nanoparticles produced from Cedecea sp. exhibit antibiofilm activity and remarkable stability.

Authors:  Priyanka Singh; Santosh Pandit; Carsten Jers; Abhayraj S Joshi; Jørgen Garnæs; Ivan Mijakovic
Journal:  Sci Rep       Date:  2021-06-16       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.